Fyarro

Have cardiopulmonary resuscitation medication and equipment readily available. Monitor for infusion reactions at least 2hrs after the 1^st infusion, during and after each subsequent infusion as clinically needed. Withhold, resume at reduced dose, or permanently discontinue based on severity and type of adverse reaction. Obtain CBCs at baseline, every 2 months for the 1^st year of treatment, and every 3 months thereafter, or more frequently if clinically indicated. Monitor K⁺ levels prior to initiation; give K⁺ supplementation as medically indicated. Monitor fasting serum glucose prior to initiation, every 3 months during therapy, or as clinically indicated (more frequently in diabetics). Update vaccinations according to current guidelines prior to initiation. Avoid close contact with those who have received live vaccines during treatment. Risk for transmission of infectious agents (eg, viral diseases, Creutzfeldt-Jakob Disease). Severe hepatic impairment: not recommended. Embryo-fetal toxicity. Advise to use effective contraception during and for 12 weeks after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 2 weeks after the last dose).